{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T22:58:40Z","timestamp":1781823520546,"version":"3.54.5"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,14]]},"DOI":"10.7759\/cureus.50524","type":"journal-article","created":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T16:43:26Z","timestamp":1702572206000},"source":"Crossref","is-referenced-by-count":6,"title":["Fibroblast Growth Factor 21: A More Effective Biomarker Than Free Fatty Acids and Other Insulin Sensitivity Measures for Predicting Non-alcoholic Fatty Liver Disease in Saudi Arabian Type 2 Diabetes Patients"],"prefix":"10.7759","author":[{"given":"Suhad","family":"Bahijri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basmah","family":"Eldakhakhny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumia","family":"Enani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghada","family":"Ajabnoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa S","family":"Al-Mowallad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubna","family":"Alsheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amani","family":"Alhozali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliaa A","family":"Alamoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwar","family":"Borai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaakko","family":"Tuomilehto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2015.80","article-title":"Nonalcoholic fatty liver disease","volume":"1","author":"Brunt EM","year":"2015","unstructured":"Brunt EM, Wong VW, Nobili V, et al.. Nonalcoholic fatty liver disease. Nat Rev Dis Primers. 2015, 1:15080. 10.1038\/nrdp.2015.80","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v7.i11.1450","article-title":"Non-alcoholic fatty liver disease in 2015","volume":"7","author":"Ahmed M","year":"2015","unstructured":"Ahmed M. Non-alcoholic fatty liver disease in 2015. World J Hepatol. 2015, 7:1450-9. 10.4254\/wjh.v7.i11.1450","journal-title":"World J Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2016.01.001","article-title":"Non-alcoholic fatty liver disease and diabetes","volume":"65","author":"Hazlehurst JM","year":"2016","unstructured":"Hazlehurst JM, Woods C, Marjot T, Cobbold JF, Tomlinson JW. Non-alcoholic fatty liver disease and diabetes. Metabolism. 2016, 65:1096-108. 10.1016\/j.metabol.2016.01.001","journal-title":"Metabolism"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi ZM","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016, 64:73-84. 10.1002\/hep.28431","journal-title":"Hepatology"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi ZM","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023, 77:1335-47. 10.1097\/HEP.0000000000000004","journal-title":"Hepatology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.4103\/sjg.SJG_122_18","article-title":"Nonalcoholic fatty liver disease burden - Saudi Arabia and United Arab Emirates, 2017-2030","volume":"24","author":"Alswat K","year":"2018","unstructured":"Alswat K, Aljumah AA, Sanai FM, et al.. Nonalcoholic fatty liver disease burden - Saudi Arabia and United Arab Emirates, 2017-2030. Saudi J Gastroenterol. 2018, 24:211-9. 10.4103\/sjg.SJG_122_18","journal-title":"Saudi J Gastroenterol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.01.009","article-title":"Non-alcoholic fatty liver disease: the mist gradually clears","volume":"48 Suppl 1","author":"de Alwis NM","year":"2008","unstructured":"de Alwis NM, Day CP. Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol. 2008, 48 Suppl 1:S104-12. 10.1016\/j.jhep.2008.01.009","journal-title":"J Hepatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2304-3881.2015.01.03","article-title":"Fatty liver disease in diabetes mellitus","volume":"4","author":"Bhatt HB","year":"2015","unstructured":"Bhatt HB, Smith RJ. Fatty liver disease in diabetes mellitus. Hepatobiliary Surg Nutr. 2015, 4:101-8. 10.3978\/j.issn.2304-3881.2015.01.03","journal-title":"Hepatobiliary Surg Nutr"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2013.41","article-title":"Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis","volume":"10","author":"Anstee QM","year":"2013","unstructured":"Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013, 10:330-44. 10.1038\/nrgastro.2013.41","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: a multisystem disease","volume":"62","author":"Byrne CD","year":"2015","unstructured":"Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015, 62:S47-64. 10.1016\/j.jhep.2014.12.012","journal-title":"J Hepatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2010.18","article-title":"Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study","volume":"105","author":"Adams LA","year":"2010","unstructured":"Adams LA, Harmsen S, St Sauver JL, Charatcharoenwitthaya P, Enders FB, Therneau T, Angulo P. Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. Am J Gastroenterol. 2010, 105:1567-73. 10.1038\/ajg.2010.18","journal-title":"Am J Gastroenterol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.4103\/1319-3767.237645","article-title":"Erratum: nonalcoholic fatty liver disease burden - Saudi Arabia and United Arab Emirates, 2017-2030","volume":"24","year":"2018","unstructured":"Erratum. nonalcoholic fatty liver disease burden - Saudi Arabia and United Arab Emirates, 2017-2030. Saudi J Gastroenterol. 2018, 24:255. 10.4103\/1319-3767.237645","journal-title":"Saudi J Gastroenterol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/diseases11010010","article-title":"Exploring the validity of available markers and indices in the diagnosis of nonalcoholic fatty liver disease (NAFLD) in people with type 2 diabetes in Saudi Arabia","volume":"11","author":"Ajabnoor GM","year":"2023","unstructured":"Ajabnoor GM, Bahijri SM, Enani SM, et al.. Exploring the validity of available markers and indices in the diagnosis of nonalcoholic fatty liver disease (NAFLD) in people with type 2 diabetes in Saudi Arabia. Diseases. 2023, 11:10.3390\/diseases11010010","journal-title":"Diseases"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2015.9","article-title":"Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23","volume":"15","author":"Degirolamo C","year":"2016","unstructured":"Degirolamo C, Sabb\u00e0 C, Moschetta A. Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. Nat Rev Drug Discov. 2016, 15:51-69. 10.1038\/nrd.2015.9","journal-title":"Nat Rev Drug Discov"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2012.11.001","article-title":"Circulating fibroblast growth factors as metabolic regulators--a critical appraisal","volume":"16","author":"Angelin B","year":"2012","unstructured":"Angelin B, Larsson TE, Rudling M. Circulating fibroblast growth factors as metabolic regulators--a critical appraisal. Cell Metab. 2012, 16:693-705. 10.1016\/j.cmet.2012.11.001","journal-title":"Cell Metab"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24726","article-title":"Ethnicity and nonalcoholic fatty liver disease","volume":"55","author":"Bambha K","year":"2012","unstructured":"Bambha K, Belt P, Abraham M, et al.. Ethnicity and nonalcoholic fatty liver disease. Hepatology. 2012, 55:769-80. 10.1002\/hep.24726","journal-title":"Hepatology"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3945\/ajcn.110.001941","article-title":"Fibroblast growth factor 21 is a metabolic regulator that plays a role in the adaptation to ketosis","volume":"93","author":"Domouzoglou EM","year":"2011","unstructured":"Domouzoglou EM, Maratos-Flier E. Fibroblast growth factor 21 is a metabolic regulator that plays a role in the adaptation to ketosis. Am J Clin Nutr. 2011, 93:901S-5. 10.3945\/ajcn.110.001941","journal-title":"Am J Clin Nutr"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/med.21390","article-title":"Fibroblast growth factor 21 as an emerging therapeutic target for type 2 diabetes mellitus","volume":"36","author":"So WY","year":"2016","unstructured":"So WY, Leung PS. Fibroblast growth factor 21 as an emerging therapeutic target for type 2 diabetes mellitus. Med Res Rev. 2016, 36:672-704. 10.1002\/med.21390","journal-title":"Med Res Rev"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.25026","article-title":"The role of FGF21 in type 1 diabetes and its complications","volume":"14","author":"Zhang J","year":"2018","unstructured":"Zhang J, Weng W, Wang K, Lu X, Cai L, Sun J. The role of FGF21 in type 1 diabetes and its complications. Int J Biol Sci. 2018, 14:1000-11. 10.7150\/ijbs.25026","journal-title":"Int J Biol Sci"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2015.00147","article-title":"Research perspectives on the regulation and physiological functions of FGF21 and its association with NAFLD","volume":"6","author":"Inagaki T","year":"2015","unstructured":"Inagaki T. Research perspectives on the regulation and physiological functions of FGF21 and its association with NAFLD. Front Endocrinol (Lausanne). 2015, 6:147. 10.3389\/fendo.2015.00147","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-018-2860-6","article-title":"Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease","volume":"75","author":"Ipsen DH","year":"2018","unstructured":"Ipsen DH, Lykkesfeldt J, Tveden-Nyborg P. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell Mol Life Sci. 2018, 75:3313-27. 10.1007\/s00018-018-2860-6","journal-title":"Cell Mol Life Sci"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.11.049","article-title":"Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease","volume":"146","author":"Lambert JE","year":"2014","unstructured":"Lambert JE, Ramos-Roman MA, Browning JD, Parks EJ. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology. 2014, 146:726-35. 10.1053\/j.gastro.2013.11.049","journal-title":"Gastroenterology"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-013-0758-5","article-title":"Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease","volume":"48","author":"Kawano Y","year":"2013","unstructured":"Kawano Y, Cohen DE. Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. J Gastroenterol. 2013, 48:434-41. 10.1007\/s00535-013-0758-5","journal-title":"J Gastroenterol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-48382-5_19","article-title":"Non-alcoholic fatty liver disease","volume":"960","author":"Engin A","year":"2017","unstructured":"Engin A. Non-alcoholic fatty liver disease. Adv Exp Med Biol. 2017, 960:443-67. 10.1007\/978-3-319-48382-5_19","journal-title":"Adv Exp Med Biol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman SL","year":"2018","unstructured":"Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018, 24:908-22. 10.1038\/s41591-018-0104-9","journal-title":"Nat Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1172\/JCI22422","article-title":"Molecular mediators of hepatic steatosis and liver injury","volume":"114","author":"Browning JD","year":"2004","unstructured":"Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest. 2004, 114:147-52. 10.1172\/JCI22422","journal-title":"J Clin Invest"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000107251.49515.c2","article-title":"Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure","volume":"42","author":"Chobanian AV","year":"2003","unstructured":"Chobanian AV, Bakris GL, Black HR, et al.. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003, 42:1206-52. 10.1161\/01.HYP.0000107251.49515.c2","journal-title":"Hypertension"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews DR","year":"1985","unstructured":"Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985, 28:412-9. 10.1007\/BF00280883","journal-title":"Diabetologia"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.85.7.6661","article-title":"Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans","volume":"85","author":"Katz A","year":"2000","unstructured":"Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000, 85:2402-10. 10.1210\/jcem.85.7.6661","journal-title":"J Clin Endocrinol Metab"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0152559","article-title":"The prevalence of diabetes and prediabetes in the adult population of Jeddah, Saudi Arabia--a community-based survey","volume":"11","author":"Bahijri SM","year":"2016","unstructured":"Bahijri SM, Jambi HA, Al Raddadi RM, Ferns G, Tuomilehto J. The prevalence of diabetes and prediabetes in the adult population of Jeddah, Saudi Arabia--a community-based survey. PLoS One. 2016, 11:e0152559. 10.1371\/journal.pone.0152559","journal-title":"PLoS One"},{"key":"ref31","unstructured":"IDF Diabetes Atlas. (2021). Accessed. November 2023: https:\/\/www.diabetesatlas.org."},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/s0016-5085(98)70599-2","article-title":"Steatohepatitis: a tale of two \"hits\"?","volume":"114","author":"Day CP","year":"1998","unstructured":"Day CP, James OF. Steatohepatitis: a tale of two \"hits\"?. Gastroenterology. 1998, 114:842-5. 10.1016\/s0016-5085(98)70599-2","journal-title":"Gastroenterology"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.10.014","article-title":"Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis","volume":"132","author":"Ota T","year":"2007","unstructured":"Ota T, Takamura T, Kurita S, et al.. Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis. Gastroenterology. 2007, 132:282-93. 10.1053\/j.gastro.2006.10.014","journal-title":"Gastroenterology"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-47269-4","article-title":"Markers of insulin resistance associated with non-alcoholic fatty liver disease in non-diabetic population","volume":"13","author":"Zeng P","year":"2023","unstructured":"Zeng P, Cai X, Yu X, Gong L. Markers of insulin resistance associated with non-alcoholic fatty liver disease in non-diabetic population. Sci Rep. 2023, 13:20470. 10.1038\/s41598-023-47269-4","journal-title":"Sci Rep"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1177\/03000605231204462","article-title":"HOMA-IR is an effective biomarker of non-alcoholic fatty liver disease in non-diabetic population","volume":"51","author":"Zeng P","year":"2023","unstructured":"Zeng P, Cai X, Yu X, Huang L, Chen X. HOMA-IR is an effective biomarker of non-alcoholic fatty liver disease in non-diabetic population. J Int Med Res. 2023, 51:3000605231204462. 10.1177\/03000605231204462","journal-title":"J Int Med Res"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.5812\/hepatmon.98531","article-title":"The incidence and risk factors of non-alcoholic fatty liver disease: a cohort study from Iran","volume":"20","author":"Motamed N","year":"2020","unstructured":"Motamed N, Khoonsari M, Panahi M, et al.. The incidence and risk factors of non-alcoholic fatty liver disease: a cohort study from Iran. Hepat Mon. 2020, 20:98531. 10.5812\/hepatmon.98531","journal-title":"Hepat Mon"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2015.11.019","article-title":"Optimal cutoff points for HOMA-IR and QUICKI in the diagnosis of metabolic syndrome and non-alcoholic fatty liver disease: a population based study","volume":"30","author":"Motamed N","year":"2016","unstructured":"Motamed N, Miresmail SJ, Rabiee B, Keyvani H, Farahani B, Maadi M, Zamani F. Optimal cutoff points for HOMA-IR and QUICKI in the diagnosis of metabolic syndrome and non-alcoholic fatty liver disease: a population based study. J Diabetes Complications. 2016, 30:269-74. 10.1016\/j.jdiacomp.2015.11.019","journal-title":"J Diabetes Complications"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1038\/srep05832","article-title":"Association between serum free fatty acid levels and nonalcoholic fatty liver disease: a cross-sectional study","volume":"4","author":"Zhang J","year":"2014","unstructured":"Zhang J, Zhao Y, Xu C, Hong Y, Lu H, Wu J, Chen Y. Association between serum free fatty acid levels and nonalcoholic fatty liver disease: a cross-sectional study. Sci Rep. 2014, 4:5832. 10.1038\/srep05832","journal-title":"Sci Rep"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-017-0551-1","article-title":"Free fatty acids profile among lean, overweight and obese non-alcoholic fatty liver disease patients: a case - control study","volume":"16","author":"Feng R","year":"2017","unstructured":"Feng R, Luo C, Li C, et al.. Free fatty acids profile among lean, overweight and obese non-alcoholic fatty liver disease patients: a case - control study. Lipids Health Dis. 2017, 16:165. 10.1186\/s12944-017-0551-1","journal-title":"Lipids Health Dis"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.3390\/nu11030677","article-title":"Impact of nutritional changes on nonalcoholic fatty liver disease","volume":"11","author":"Perdomo CM","year":"2019","unstructured":"Perdomo CM, Fr\u00fchbeck G, Escalada J. Impact of nutritional changes on nonalcoholic fatty liver disease. Nutrients. 2019, 11:677. 10.3390\/nu11030677","journal-title":"Nutrients"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-1983","article-title":"Dietary fat content modifies liver fat in overweight nondiabetic subjects","volume":"90","author":"Westerbacka J","year":"2005","unstructured":"Westerbacka J, Lammi K, H\u00e4kkinen AM, Rissanen A, Salminen I, Aro A, Yki-J\u00e4rvinen H. Dietary fat content modifies liver fat in overweight nondiabetic subjects. J Clin Endocrinol Metab. 2005, 90:2804-9. 10.1210\/jc.2004-1983","journal-title":"J Clin Endocrinol Metab"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0131664","article-title":"Combined serum biomarkers in non-invasive diagnosis of non-alcoholic steatohepatitis","volume":"10","author":"Yang M","year":"2015","unstructured":"Yang M, Xu D, Liu Y, et al.. Combined serum biomarkers in non-invasive diagnosis of non-alcoholic steatohepatitis. PLoS One. 2015, 10:e0131664. 10.1371\/journal.pone.0131664","journal-title":"PLoS One"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2021.06.024","article-title":"Ethnicity-specific alterations of plasma and hepatic lipidomic profiles are related to high NAFLD rate and severity in Hispanic Americans, a pilot study","volume":"172","author":"Mazi TA","year":"2021","unstructured":"Mazi TA, Borkowski K, Newman JW, et al.. Ethnicity-specific alterations of plasma and hepatic lipidomic profiles are related to high NAFLD rate and severity in Hispanic Americans, a pilot study. Free Radic Biol Med. 2021, 172:490-502. 10.1016\/j.freeradbiomed.2021.06.024","journal-title":"Free Radic Biol Med"},{"key":"ref44","article-title":"Fibroblast growth factor-21 and omentin-1 hepatic mRNA expression and serum levels in morbidly obese women with non-alcoholic fatty liver disease","volume":"68","author":"Waluga M","year":"2017","unstructured":"Waluga M, Kukla M, Zorniak M, et al.. Fibroblast growth factor-21 and omentin-1 hepatic mRNA expression and serum levels in morbidly obese women with non-alcoholic fatty liver disease. J Physiol Pharmacol. 2017, 68:363-74.","journal-title":"J Physiol Pharmacol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.ph.45.030183.000345","article-title":"Sexual dimorphism in the liver","volume":"45","author":"Roy AK","year":"1983","unstructured":"Roy AK, Chatterjee B. Sexual dimorphism in the liver. Annu Rev Physiol. 1983, 45:37-50. 10.1146\/annurev.ph.45.030183.000345","journal-title":"Annu Rev Physiol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1101\/gr.5217506","article-title":"Tissue-specific expression and regulation of sexually dimorphic genes in mice","volume":"16","author":"Yang X","year":"2006","unstructured":"Yang X, Schadt EE, Wang S, et al.. Tissue-specific expression and regulation of sexually dimorphic genes in mice. Genome Res. 2006, 16:995-1004. 10.1101\/gr.5217506","journal-title":"Genome Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/211380-fibroblast-growth-factor-21-a-more-effective-biomarker-than-free-fatty-acids-and-other-insulin-sensitivity-measures-for-predicting-non-alcoholic-fatty-liver-disease-in-saudi-arabian-type-2-diabetes-patients","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:10:01Z","timestamp":1707509401000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/211380-fibroblast-growth-factor-21-a-more-effective-biomarker-than-free-fatty-acids-and-other-insulin-sensitivity-measures-for-predicting-non-alcoholic-fatty-liver-disease-in-saudi-arabian-type-2-diabetes-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,14]]},"references-count":46,"URL":"https:\/\/doi.org\/10.7759\/cureus.50524","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,14]]}}}